About
Biomarker Identification, Drugs
Areas of Focus
Categories
Non-PharmaceuticalSmall Molecule PharmaceuticalBoston & New England
Team (22)
Ana Limón
Senior VicePresident of Clinical Development and Global Medical Affairs
Oryzon Genomics
team_member
Carlos Buesa
President (Executive Director)
Oryzon Genomics
executive
Dr. Alan F. Schatzberg
Oryzon Genomics
team_member
Dr. Ana Limón
Oryzon Genomics
team_member
Dr. Douglas Faller
Oryzon Genomics
team_member
Dr. Emil F. Coccaro
Oryzon Genomics
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
3
As Collaborator
3
Total Enrollment
343
By Phase
PHASE1: 3PHASE2: 3
By Status
RECRUITING: 2COMPLETED: 2NOT_YET_RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07113691Collaborator
Iadademstat + SBRT With Atezo in ES-SCLC
PHASE1Not yet recruiting
15 participants
Started: Sep 30, 2025 · Completed: Sep 30, 2029
NCT06357182Collaborator
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
PHASE1Recruiting
24 participants
Started: Aug 22, 2024 · Completed: May 29, 2026
NCT05420636Collaborator
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
PHASE2Terminated
20 participants
Started: Dec 21, 2022 · Completed: Jul 23, 2025
NCT05546580Lead Sponsor
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
PHASE1Recruiting
50 participants
Started: Nov 14, 2022 · Completed: Nov 30, 2025
NCT04932291Lead Sponsor
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PHASE2Completed
210 participants
Started: Mar 26, 2021 · Completed: Nov 13, 2023
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...